logo
  

Stock Alert: Genprex Hits New 52-week High

Shares of Genprex Inc. (GNPX) touched a new 52-week high in the morning trade on Friday, at $5.75. The stock has been rising since Tuesday and has traded in a range of $3.15 to $5.75 in the past 52 weeks.

On Tuesday, Genprex had said it entered into an exclusive license agreement with the University of Pittsburgh for a diabetes gene therapy that may have the potential to cure Type 1 and Type 2 diabetes, which together currently affect about 30.3 million people in the U.S, or 9 percent of the U.S. population. We had alerted the readers about the stock on Feb 11.

Under the agreement, the clinical-stage gene therapy company has licensed the patented diabetes gene therapy technology designed by researchers at the University of Pittsburgh. Genprex plans to pursue potential partnerships for the development of this therapy globally and in the U.S. The company will continue its focus on developing its immunogene therapies for cancer, including Oncoprex immunogene therapy, its lead drug candidate for non-small cell lung cancer, in parallel with development of the new diabetes gene therapy.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Biotech Investor.
Editors Pick
The National Restaurant Association or NRA has urged the U.S. Congress to refill the Restaurant Revitalization Fund or RRF, which is expected to save more than 1.6 million jobs in the restaurant industry hit hard by the surge in Omicron Variant. In a letter to Congress, the association highlighted, based on its survey on 4,200 restaurant operators, the devastating impact so far on the industry... Industrial conglomerate General Electric Co. reported Tuesday a net loss for the fourth quarter compared to a profit last year, hurt by steep debt extinguishment costs and lower revenues. However, adjusted earnings per share topped analysts' expectations, while quarterly revenues missed them. Shares of LM Ericsson were gaining more than 7 percent in Swedish trading as well as in pre-market activity on Nasdaq, after the telecom equipment maker reported Tuesday higher profit and sales in its fourth quarter with strong demand. Further, the company lifted its full-year dividend, and maintained targets for fiscal 2022 EBIT growth as well as long-term target of EBITA margin.
RELATED NEWS
Follow RTT